NCT06825156View on ClinicalTrials.gov

Metabolic and Renal Outcomes in Cardiac Surgery Patients Receiving SGLT2 Inhibitors

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 3, 2022

Primary Completion Date

May 26, 2023

Study Completion Date

May 26, 2023

Conditions
Acute Kidney Injury
Interventions
DRUG

Empagliflozin 10 MG

Patients receive 10mg Empagliflozin(SLGT-2i) daily from 3 days prior to surgery untill 2 days post-surgery which includes day of surgery.

Trial Locations (1)

1105 AZ

Amsterdam University Medical Centre, Amsterdam-Zuidoost

All Listed Sponsors
collaborator

European Commission

OTHER

lead

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

OTHER